— Know what they know.
Not Investment Advice

CLCS OTC

Cell Source, Inc.
1W: +12.0% 1M: -47.2% 3M: -46.3% YTD: -6.0% 1Y: +11.9% 3Y: -26.6% 5Y: -6.0%
$0.47
+0.06 (+14.61%)
 
Weekly Expected Move ±33.2%
$0 $0 $0 $1 $1
OTC · Healthcare · Biotechnology · Tech Score Strong Sell · Power 31 · $31.9M mcap · 55M float · 0.0057% daily turnover · Short 52% of daily vol

Balance Sheet Trends

Total Assets
$286K +46.8% ▲
5Y CAGR: +20.1%
Total Liabilities
$19M +20.7% ▲
5Y CAGR: +26.6%
Shareholders Equity
-$19M -20.4% ▼
Cash & Investments
$75K +236.1% ▲
5Y CAGR: +21.7%
Total Debt
$10M +8.8% ▲
5Y CAGR: +31.1%
Net Debt
$10M +8.2% ▲

Assets vs Liabilities & Equity

Year-over-Year Growth

View Full Balance Sheet
Line ItemFY2020FY2021FY2022FY2023FY2024
— Assets —
Cash$245K$93K$223K$22K$75K
Short-Term Investments$0$0$0$0$0
Cash & ST Investments$245K$93K$223K$22K$75K
Net Receivables$0$0$0$0$50K
Inventory$0$0$0$0$0
Other Current Assets$30K$17K$23K$12K$1K
Total Current Assets$452K$314K$410K$195K$286K
Property, Plant & Equip.$0$0$0$0$0
Goodwill & Intangibles$0$0$0$0$0
Long-Term Investments$0$0$0$0$0
Other Non-Current Assets$4K$0$0$173.0B$0
Total Non-Current Assets$4K$0$0$173.0B$0
Total Assets$452K$314K$410K$195K$286K
— Liabilities —
Accounts Payable$193K$223K$680K$1M$2M
Short-Term Debt$5M$6M$8M$9M$10M
Deferred Revenue$0$3M$0$0$0
Other Current Liabilities$321K-$573K$240K$4M$6M
Total Current Liabilities$8M$10M$13M$16M$19M
Long-Term Debt$0$0$0$0$0
Other Non-Current Liab.$0$0$0$0$0
Total Non-Current Liabilities$0$7M$0$0$0
Total Liabilities$8M$10M$13M$16M$19M
— Equity —
Common Stock$33K$34K$36K$40K$45K
Retained Earnings-$26M-$31M-$36M-$42M-$46M
Accumulated OCI$0$0$0$0$0
Total Stockholders Equity-$8M-$10M-$13M-$16M-$19M
Total Liabilities & Equity$452K$314K$410K$195K$286K
— Key Metrics —
Total Debt$5M$6M$8M$9M$10M
Net Debt$5M$6M$8M$9M$10M
Total Investments$0$0$0$0$0

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms